Columns

Patience Is a Requirement for Good Caregiving

My wife, Jill, who is gene-positive with Huntington’s disease (HD), is a born caregiver. It’s one of the reasons I fell in love with her. I watched her take care of her father, who also was diagnosed with HD, as he started to decline physically and mentally. It was an…

NeuExcell, Spark to Develop Neuroregenerative Gene Therapy

NeuExcell Therapeutics has entered into a research deal with Spark Therapeutics to advance the development of a safe and effective neuroregenerative gene therapy for Huntington’s disease. Under the terms of the agreement, Spark, a member of the Roche Group, will have access to NeuExcell’s gene therapy platform…

The People Involved in Freeze HD Warm My Heart

On Saturday evening, my wife, Jill, and I will be putting on our fancy party clothes to attend the 7th Annual Freeze HD virtual event. The benefit will feature celebrities, music performances, and a silent auction, with the goal of raising money for the Huntington’s Disease Society of America.

Dosing Starts in SELECT-HD Trial That Seeks to Lower mHTT Levels

A Phase 1/2 trial evaluating Wave Life Science’s investigational therapy WVE-003 for Huntington’s disease has started dosing patients, the company has announced. The SELECT-HD trial (NCT05032196), underway in clinical sites in Australia, Germany, Poland, and the U.K., is currently looking to enroll 36 Huntington’s patients, ages…

Abnormal DNA Repair Mechanism May Be Therapeutic Target

The interaction between FAN1 and MLH1 — two DNA repair proteins known to be genetic modifiers of Huntington’s disease — protects against further expansion of disease-causing CAG repeats, according to a study using human and mouse models of the disease. Specifically, this interaction prevents MLH1’s recruitment to a DNA…